Missed or late GLP-1 shot: what actually happens to your appetite
A flight gets rebooked, the pen is in checked luggage that lands a day late, or the fridge at the Airbnb turns out to not exist. Whatever the reason, the weekly shot slips by two, four, ten days. By day five the appetite is back, sometimes harder than before, and the first instinct is to search whether the drug "stopped working." It didn't. Something more specific and more explainable happened, and it's worth knowing what before you decide what to do about the next dose.
Why the appetite comes back before the drug is "gone"
GLP-1 drugs (semaglutide, tirzepatide, retatrutide) aren't topping up a deficiency the way, say, insulin does for a diabetic. Bodyweight is a running computation your brain does with GLP-1, GIP, glucagon, insulin, and sex hormones as inputs, a set-point system. A weekly GLP-1 shot is a large "don't eat as much" signal laid on top of that computation, not a replacement for it. Take the signal away, even temporarily, and the underlying set-point math it was overriding is still there, waiting to reassert itself. That's why the rebound can feel sudden: it isn't the drug wearing off gradually so much as a strong override lifting.
This is also why the field has never solved the "stopping at max dose causes regain toward baseline" problem. Pharma trial designs weren't built to answer it, and there's still no good published taper guidance from the drugmakers themselves. A missed week from a suitcase mishap isn't the same as a deliberate stop, but it's pulling on the same lever.
The standard model treats these drugs as chronic, not cyclical
The default clinical framing for GLP-1s is: titrate up slowly, then hold that dose indefinitely. Unlike a GH secretagogue or BPC-157, where cycling on and off is the norm, GLP-1s are run continuously. That's the backdrop against which a missed dose reads as a deviation, not a feature.
There's a real divergent opinion worth naming honestly, because it's out there in the wild and you'll see it if you read enough. Some clinicians who microdose GLP-1s for metabolically healthy patients deliberately space doses out over time (weekly, then every two weeks, then monthly) on the logic that it lets receptors resensitize, similar to how testosterone cycling works. That's a real clinical position held by named practitioners, but it's explicitly outside the standard of care for a therapeutic weight-loss dose, and it's built around planned, monitored spacing, not an accidental gap from a missed flight connection. Don't read "some doctors deliberately space doses" as "so an accidental gap is fine." Those are different situations with different monitoring behind them.
What not to do when you're back
The instinct to "make up for it" by taking a bigger dose at the next injection is the one worth naming explicitly, because it's the version most likely to backfire. Clinicians who watch this closely describe most of the severe GI reactions on these drugs (nausea, vomiting) as a consequence of ramping the dose too fast, more than the drug itself at a given dose. That's why the standard playbook titrates new patients up gradually. Jumping a step, or effectively double-dosing to compensate for a missed week, risks reproducing the exact pattern titration exists to avoid. Whether to resume at the same dose, hold a step back, or do something else belongs to whoever manages your prescription. This isn't a decision to make solo based on a forum thread.
The rebound has a documented lag, and that's useful
One thing that is characterized, because clinics that run deliberate step-downs have to plan around it: rebound appetite doesn't hit the moment a dose lapses. In one clinical taper protocol, appetite rebound is documented to lag each planned dose reduction by roughly one to two weeks, rather than appearing instantly. The countermeasures built for that planned taper (holding protein around 1.8 to 2.0 g/kg of goal bodyweight, 30 to 40 g of fiber a day, leaning on satiating fats, keeping meals structured instead of grazing, and resuming food logging) exist because the appetite signal doesn't vanish cleanly, it fades and then swings back. An accidental gap isn't the same as a planned taper, but the same underlying mechanism is doing the work, so the lag and the countermeasures are a reasonable starting reference point, worth confirming with whoever manages your prescription rather than assuming.
Is this actually worth flagging, or is it noise
Not every missed dose needs an anxious message to your provider, but a few signals help separate a normal appetite swing from something worth actually raising. If hunger and cravings show up and settle within roughly the expected window, that's the set-point mechanism doing what it does, not a sign the drug has "stopped working" for good. What's worth flagging: a resting heart rate or HRV trend from a wearable that shifts and doesn't recover, GI symptoms that are new rather than a rerun of the ones you had during initial titration, or a gap long enough that you're genuinely unsure whether to resume at the same dose. None of those are things to self-diagnose from a Reddit thread; they're exactly the kind of pattern a clinician reviewing your case would want to know about.
The actual takeaway
A missed or delayed GLP-1 shot is common enough that it shouldn't trigger panic, and the appetite spike that follows has a real, explainable mechanism behind it rather than being a mystery or a sign of failure. What it isn't is a green light to self-correct with a bigger next dose. That instinct, more than the missed week itself, is what turns an inconvenience into a GI event. Treat the gap as a data point for whoever manages your prescription, not a problem to solve alone.
For background on evaluating who's actually behind a sourcing or prescribing relationship, see how to vet a peptide seller. For more on what happens after a GLP-1 protocol changes shape, see how restarting after a break plays out, and what's documented about discontinuation symptoms that persist. More breakdowns like this live on the Ouros Lab blog.
FAQ
Does missing one GLP-1 shot mean starting over from the lowest dose?
There's no single published rule for this. It depends on how long the gap was and where you were in titration, and it's a call for whoever manages your prescription to make, not something to decide from a forum thread.
Why does appetite come back so fast after just one missed dose?
The drug isn't a slow-release deficiency fix, it's a strong signal layered on top of your brain's own bodyweight set-point system. Remove the signal and the underlying set-point math, which never went away, reasserts itself. In one clinical taper protocol, that rebound is documented to lag a planned dose reduction by roughly one to two weeks rather than hitting instantly, a useful reference point even if your gap wasn't planned.
Is it safe to just take a bigger dose next time to catch up?
This is the one instinct worth resisting on your own. Clinicians who watch this closely describe most severe GI side effects on GLP-1s as coming from ramping the dose too fast, not from the drug itself, which is exactly what titration schedules exist to prevent. Whether and how to resume is a conversation with your prescriber.
Do GLP-1s need to be cycled like some other peptides?
No, the standard model runs them continuously once titrated, unlike GH secretagogues or BPC-157, which have community cycling norms. A minority clinical view deliberately spaces doses for specific, monitored, non-standard cases, but that's not the same as an accidental gap.